Dentsply Sirona (NASDAQ:XRAY) Bolsa

Dentsply Sirona

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).

Dentsply Sirona Inc

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.29%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On March 24, Bristol Myers Squibb received positive CHMP opinion for subcutaneous formulation of Opdiv across multiple solid tumor indications.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">latest BMY news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="906" height="817" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43.png" alt="" class="wp-image-857124" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43-768x693.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</h3>
<ul>
<li>Dividend Yield: 4.70%</li>
<li>Morgan Stanley analyst Erin Wright maintained an Overweight rating and cut the price target from $30 to $23 on Dec. 17, 2024. This analyst has an accuracy rate of 75%.</li>
<li>UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $35 to $27 on Dec. 3, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On March 17, Dentsply Sirona named David Ferguson as Global Business Unit Leader.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest XRAY <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="910" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13.png" alt="" class="wp-image-857125" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13-768x690.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 5.88%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and raised the price target from $13 to $14 on Dec. 6, 2024. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Jason Gerberry downgraded the stock from Neutral to Underperform with a price target of $9 on Oct. 23, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: Viatris will report first quarter financial results on Thursday, May 8.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest VTRS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="913" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14.png" alt="" class="wp-image-857127" style="width:526px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14-768x690.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

VTRS

XRAY

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</h3>
<ul>
<li>Dividend Yield: 4.11%</li>
<li>Mizuho analyst Steven Valiquette maintained a Neutral rating and cut the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Overweight rating and cut the price target from $30 to $23 on Dec. 17, 2024. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On March 17, Dentsply Sirona named David Ferguson as Global Business Unit Leader.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">XRAY news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/6dde7dcc-8523-415e-8b9a-848a09b31f98" alt="" style="width:509px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.06%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Cantor Fitzgerald analyst Olivia Brayer maintained a Neutral rating and increased the price target from $50 to $55 on Feb. 4, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On March 14, the European Commission (EC) approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy..</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 3.97%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On March 20, CVS Health reported its board of directors has approved a quarterly dividend of 66.5 cents per share on the Common Stock of the Corporation.</li>
<li>Edge Stock Ratings:&nbsp;62.89 Momentum score with Value at 40.46. <a href="https://www.benzinga.com/quote/CCU" target="_blank" rel="noreferrer noopener"></a></li>
</ul>

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="470" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217.png" alt="" class="wp-image-838055" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217.png 470w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217-300x120.png 300w" sizes="(max-width: 470px) 100vw, 470px" /></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Want Edge Stock Rankings on this stock?&nbsp;<a href="https://www.benzinga.com/quote/CELH" target="_blank" rel="noreferrer noopener">Become an Edge subscriber here</a>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44434941/how-to-earn-500-a-month-from-kb-home-stock-ahead-of-q1-earnings">How To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings</a></li>
</ul>
Photo: Shutterstock

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) and ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) show below-market growth and have no meaningful upside, <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">according Needham analysts</a>.
What Happened: Needham downgraded the two dental companies to Hold.
ZimVie reported adjusted EPS of 27 cents, beating the consensus of 26 cents. The company&#8217;s sales of $111.52 million fell below the <a href="https://www.benzinga.com/pressreleases/25/02/g43989465/zimvie-reports-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">consensus of $113.4 million</a>.
Dentsply Sirona, meanwhile, reported fourth-quarter adjusted earnings per share of 26 cents. It missed the street view of 43 cents. Quarterly sales of $905 million (down 10.6% year over year) missed the analyst consensus estimate of $920.56 million. Organic Sales <a href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" target="_blank" rel="noreferrer noopener">fell 10.7% year over year</a>.
In February, consumer sentiment in the U.S. declined. The University of Michigan&#8217;s Consumer Sentiment Index <a href="https://www.benzinga.com/general/market-summary/25/02/43889033/consumer-sentiment-drops-10-unitedhealth-under-investigation-whats-driving-markets-friday" target="_blank" rel="noreferrer noopener">dropped to 64.7 from 71.1</a> in January (initially reported as 73.2). Dental firms&#8217; management looks at consumer sentiment to gauge consumers&#8217; willingness to spend on dental care.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" rel="noreferrer noopener">Dentsply Sirona Q4: Earnings Miss, 10% Sales Drop, Soft 2025 Outlook And More</a>
Why It Matters: Interest rates play a key role because major purchases are usually financed. While some rate cuts may start around midyear, high interest rates will likely continue to weigh on capital demand.
Adding to these challenges, ongoing staffing shortages in the provider market could limit capacity even if patient demand increases.
Analyst David Saxon writes that Dentsply Sirona continues to lose market share. The company is overexposed to equipment, he argues. That has been one of the softest product categories in dentistry, he adds. Low-cost/value launches from competitors have created pricing pressure, and interest rates remain a headwind to demand.
ZimVie is also losing implant market share — 60% of its portfolio. The company has upcoming initiatives meant to drive improved execution. The analyst expects it will take time for these to get ZimVie&#8217;s growth to be at or above the market&#8217;s growth.
Needham also comments on tariff exposure on another dental player, Align Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>).
The clear aligners and iTero sleeves are covered under the USMCA (US-Mexico-Canada Agreement) and are exempt from tariffs until April 2025
Price Action: ALGN stock is down 3.59% at $158.66. XRAY stock is down 2.28% at $14.98. ZIMV stock is down 6.64% at $11.81 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44306214/gm-and-pge-team-up-to-let-evs-power-homes-offer-up-to-4500-in-energy-incentives" target="_blank" rel="noreferrer noopener">GM And PG&amp;E Team Up To Let EVs Power Homes, Offer Up To $4,500 In Energy Incentives</a></li>
</ul>

Downgrades

Health Care

Movers

General

ALGN

ZIMV

Dental Players Dentsply Sirona, ZimVie Show Weak Growth Outlook: Analyst

Mizuho analyst Steven Valiquette maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Neutral and lowers the price target from $21 to $18.

Mizuho Maintains Neutral on Dentsply Sirona, Lowers Price Target to $18

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Brad Sills downgraded the rating for UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Neutral to Underperform and lowered the price target from $18 to $10. UiPath shares closed at $11.83 on Wednesday. <a href="https://www.benzinga.com/quote/path/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Ryan Kenny downgraded Moelis &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) from Overweight to Underweight and lowered the price target from $100 to $70. Moelis shares closed at $60.09 on Wednesday. <a href="https://www.benzinga.com/quote/mc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst David Saxon downgraded the rating for DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Buy to Hold. Dentsply Sirona shares closed at $15.33 on Wednesday. <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Ki Bin Kim downgraded Federal Realty Investment Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Buy to Hold and lowered the price target from $114 to $105. Federal Realty Investment shares closed at $97.12 on Wednesday. <a href="https://www.benzinga.com/quote/FRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst David Saxon downgraded the rating for ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) from Buy to Hold. ZimVie shares closed at $12.65 on Wednesday. <a href="https://www.benzinga.com/quote/ZIMV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PATH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-1024x595.png" alt="" class="wp-image-822803" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday">Adobe, Intel And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

PATH

This UiPath Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Needham analyst David Saxon downgrades Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Buy to Hold.

Needham Downgrades Dentsply Sirona to Hold

Wells Fargo analyst Vik Chopra maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Equal-Weight and lowers the price target from $20 to $19.

Wells Fargo Maintains Equal-Weight on Dentsply Sirona, Lowers Price Target to $19

Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and lowers the price target from $24 to $20.

Barrington Research Maintains Outperform on Dentsply Sirona, Lowers Price Target to $20

Baird analyst Jeffrey Johnson maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Neutral and lowers the price target from $22 to $20.

Baird Maintains Neutral on Dentsply Sirona, Lowers Price Target to $20

In the last three months, 9 analysts have published ratings on Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dentsply Sirona, revealing an average target of $22.67, a high estimate of $27.00, and a low estimate of $20.00. Highlighting a 19.04% decrease, the current average has fallen from the previous average price target of $28.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740744053_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Dentsply Sirona among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dentsply Sirona. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Dentsply Sirona's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>All You Need to Know About Dentsply Sirona</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Dentsply Sirona's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Dentsply Sirona's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.42% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Dentsply Sirona's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -51.95%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dentsply Sirona's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -17.79%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.31%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Dentsply Sirona's debt-to-equity ratio stands notably higher than the industry average, reaching 0.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Dentsply Sirona Through The Eyes Of 9 Analysts

Needham analyst David Saxon maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $25 to $23.

Needham Maintains Buy on Dentsply Sirona, Lowers Price Target to $23

Dentsply Sirona Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Thursday.</a>
The company reported fourth-quarter adjusted earnings per share of 26 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44000815/dentsply-sirona-reports-fourth-quarter-and-full-year-2024-results-provides-full-year-2025-outlook" rel="noreferrer noopener">missing the street view of 43 cents</a>.
Quarterly sales of $905 million (down 10.6% year over year) missed the analyst consensus estimate of $920.56 million. Organic Sales fell 10.7% year over year.
Adjusted EBITDA slumped 25.9% to $128 million, while adjusted EBITDA margin contracted to 14.2% from 17.1% in the year-ago period.
&#8220;While we were pleased to see improvement in several areas of the business, Byte, persistent macro pressures and competitive dynamics negatively impacted Q4 and 2024 full year results,&#8221; said Simon Campion, President and Chief Executive Officer.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/02/44000386/trump-shuts-down-chevrons-venezuela-oil-permit-tightening-pressure-on-maduro-regime-crude-oil-prices-rise-on-supply-concerns" rel="noreferrer noopener">Trump Shuts Down Chevron&#8217;s Venezuela Oil Permit, Tightening Pressure On Maduro Regime: Crude Oil Prices Rise On Supply Concerns</a>
In the fourth quarter, the company paid $31 million in dividends, resulting in a total of $376 million returned to shareholders through dividends and share repurchases in 2024.
The company had $272 million of cash and cash equivalents as of December&nbsp;31, 2024.
&#8220;Improvements in Q4 included a return to growth in Europe and imaging globally, as well as continued growth of Wellspect Healthcare and SureSmile,&#8221; Campion adds.
Dividend: On February 26, the company declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share.
The dividend is payable on April 11 to holders of record as of March 28.
Outlook: Dentsply Sirona expects 2025 sales between $3.5 billion and $3.6 billion, below the consensus of $3.734 billion.
Organic sales are projected to decline by 2.0% to 4.0%, including a 2% impact from Byte sales.
The company anticipates adjusted EPS to range from $1.80 to $2.00, compared with the consensus of $1.90.
Price Action: XRAY shares are trading lower by 6.80% to $17.53 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43973550/photronics-q1-earnings-beats-estimates-strong-ic-demand-growth-in-high-end-products-ceo-cautious-on-2025-outlook" target="_blank" rel="noreferrer noopener">Photronics Q1 Earnings: Beats Estimates, Strong IC And FPD Demand, Growth in High-End Products, CEO Cautious on 2025 Outlook</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Guidance

Dentsply Sirona Q4: Earnings Miss, 10% Sales Drop, Soft 2025 Outlook And More

WIIM

Dentsply Sirona shares are trading lower after the company reported worse-than-expected Q4 FY24 financial results and issued guidance.

Dentsply Sirona Expects 2025 Sales Of $3.5B-$3.6B Versus Consensus Of $3.734B, down (4.0%) to (2.0%) on an organic basis, which includes a (2%) Byte sales impact, With Adjusted EPS Of $1.80-$2.00 Versus Consensus Of $1.90

Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) reported quarterly earnings of $0.26 per share which missed the analyst consensus estimate of $0.43 by 39.53 percent. This is a 40.91 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $905.00 million which missed the analyst consensus estimate of $920.56 million by 1.69 percent. This is a 10.57 percent decrease over sales of $1.01 billion the same period last year.

Dentsply Sirona Q4 2024 Adj EPS $0.26 Misses $0.43 Estimate, Sales $905.00M Miss $920.56M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Vik Chopra initiated coverage on Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with an Equal-Weight rating and announced a price target of $80. Henry Schein shares closed at $77.62 on Thursday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Michael Okunewitch initiated coverage on Mainz Biomed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) with a Buy rating and announced a price target of $14. Mainz Biomed shares closed at $6.53 on Thursday. <a href="https://www.benzinga.com/quote/MYNZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst David Williams initiated coverage on Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy rating and announced a price target of $245. Analog Devices shares closed at $209.34 on Thursday. <a href="https://www.benzinga.com/quote/ADI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Vik Chopra initiated coverage on Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with an Overweight rating and announced a price target of $255. Align Tech shares closed at $204.89 on Thursday. <a href="https://www.benzinga.com/quote/ALGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street analyst Jaeson Schmidt initiated coverage on BK Technologies Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) with a Buy rating and announced a price target of $40. BK Technologies shares closed at $28.97 on Thursday. <a href="https://www.benzinga.com/quote/BKTI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADI stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-1024x585.png" alt="" class="wp-image-783129" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14084410/image-2-43.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

Initiation

BKTI

CRSP

HSIC

MYNZ

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wells Fargo analyst Vik Chopra initiates coverage on Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Equal-Weight rating and announces Price Target of $20.

Wells Fargo Initiates Coverage On Dentsply Sirona with Equal-Weight Rating, Announces Price Target of $20

Rumors

Watching DENTSPLY SIRONA; Traders Circulate Unconfirmed Rumor An Activist Has Taken A Position And There May Be A Bidder For The Company

Needham analyst David Saxon reiterates Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and maintains $25 price target.

Reiteration

Needham Reiterates Buy on Dentsply Sirona, Maintains $25 Price Target

Press Releases

Dentsply Sirona to Host Fourth Quarter and Full Year 2024 Conference Call on February 27th

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DENTSPLY SIRONA Inc. - XRAY

Legal

DENTSPLY ALERT: Bragar Eagel & Squire, P.C. is Investigating DENTSPLY SIRONA Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Management

Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

Dentsply Sirona Initiates Review of Strategic Alternatives for Wellspect Healthcare

Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook

Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2025

Comments

Dentsply Sirona

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL